Compare Medpace Holdings Inc (MEDP) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs US Bancorp — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while US Bancorp trades at $63.93 (market cap $98.36B). The key difference: US Bancorp is far larger — about 6.5× Medpace Holdings Inc's market cap, and US Bancorp pays a 3.29% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | USB | |
|---|---|---|
Market Cap | $15.08B | $98.36B |
Sector | Technology | Financials |
52-Week High | $620.59 | $64.01 |
52-Week Low | $308.88 | $43.94 |
Enterprise Value | $14.55B | — |
Dividend Yield | — | 3.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
U.S. Bancorp (USB) trades at $63.09, down 0.08% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $69.70. Recent Q2 2026 earnings beat expectations with EPS of $1.35, driven by loan growth and fee income. Revenue reached a record $28.54B in 2025, with net income margin improving to 27.61%. The stock shows strong institutional support with 47.92% of analysts rating it a Buy.
Outlook remains positive due to earnings momentum and dividend yield near 3%, but risks include rising debt-to-asset ratios and macroeconomic sensitivity. Upside potential exists if loan growth and digital banking adoption continue, though investor caution is warranted given RSI levels indicating mild overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
